Literature DB >> 17116947

Phenomenology of delirium in cancer patients, as described by the Memorial Delirium Assessment Scale (MDAS) and the Delirium Rating Scale (DRS).

Marco Bosisio1, Augusto Caraceni, Luigi Grassi.   

Abstract

This study was based on the data collected on a consecutive sample of 106 cancer patients referred for mental status evaluation. All patients were evaluated by use of the Confusion Assessment Method (CAM) algorithm, the Delirium Rating Scale (DRS), the Memorial Delirium Assessment Scale (MDAS), and a question about the subjective perception of delirium. After comparing the diagnostic criteria of delirium on the DSM-III-R and DSM-IV, authors evaluated the ability of all DRS and MDAS items to discriminate delirium versus non-delirium patients, testing the difference in the distribution of the individual MDAS and DRS item scores. Authors also assessed the relationship between delirium diagnosis and the subjective perception of delirium. The MDAS showed a greater number of discriminating items. The items that proved to be less discriminating were "Hallucinations" and "Lability of Mood" on the DRS. Subjective perception only partially discriminated delirium from non-delirium patients. The way in which the DRS and MDAS reflected the DSM criteria are therefore partially different.

Entities:  

Mesh:

Year:  2006        PMID: 17116947     DOI: 10.1176/appi.psy.47.6.471

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  7 in total

1.  Melatonin intervention to prevent delirium in hospitalized patients: A meta-analysis.

Authors:  Wei You; Xiao-Yu Fan; Cheng Lei; Chen-Cong Nie; Yao Chen; Xue-Lian Wang
Journal:  World J Clin Cases       Date:  2022-04-26       Impact factor: 1.534

2.  Comprehensive approaches to managing delirium in patients with advanced cancer.

Authors:  Jung Hun Kang; Seong Hoon Shin; Eduardo Bruera
Journal:  Cancer Treat Rev       Date:  2012-09-06       Impact factor: 12.111

3.  Phenomenological examinations of delirium in advanced cancer patients: exploratory structural equation modelling and latent profile analysis.

Authors:  Eun-Jung Shim; Hyeju Ha; Won-Hyoung Kim; Moon-Hee Lee; Jisun Park; Kwang-Min Lee; Kyung-Lak Son; Chan-Woo Yeom; Bong-Jin Hahm
Journal:  BMC Palliat Care       Date:  2020-10-19       Impact factor: 3.234

4.  The preventative role of exogenous melatonin administration to patients with advanced cancer who are at risk of delirium: study protocol for a randomized controlled trial.

Authors:  Shirley Harvey Bush; Nathalie Lacaze-Masmonteil; Marie Theresa McNamara-Kilian; Alistair Richard MacDonald; Sallyanne Tierney; Franco Momoli; Meera Agar; David Christopher Currow; Peter Gerard Lawlor
Journal:  Trials       Date:  2016-08-11       Impact factor: 2.279

5.  JPOS/JASCC clinical guidelines for delirium in adult cancer patients: a summary of recommendation statements.

Authors:  Yoshinobu Matsuda; Hitoshi Tanimukai; Shinichiro Inoue; Shuji Inada; Koji Sugano; Hideaki Hasuo; Masafumi Yoshimura; Saho Wada; Chikako Dotani; Hiroyoshi Adachi; Yoshiaki Okamoto; Mari Takeuchi; Daisuke Fujisawa; Jun Kako; Chiyuki Sasaki; Yasuhiro Kishi; Nobuya Akizuki; Masatoshi Inagaki; Yosuke Uchitomi; Eisuke Matsushima; Toru Okuyama
Journal:  Jpn J Clin Oncol       Date:  2020-05-05       Impact factor: 3.019

6.  Delirium in Intensive Care Unit: Phenomenology, Subtypes, and Factor Structure of Symptoms.

Authors:  Sandeep Grover; Abhishek Ghosh; Siddharth Sarkar; Amit Desouza; Lakshmi Narayana Yaddanapudi; Debashish Basu
Journal:  Indian J Psychol Med       Date:  2018 Mar-Apr

7.  Melatonin to prevent delirium in patients with advanced cancer: a double blind, parallel, randomized, controlled, feasibility trial.

Authors:  Peter G Lawlor; Marie T McNamara-Kilian; Alistair R MacDonald; Franco Momoli; Sallyanne Tierney; Nathalie Lacaze-Masmonteil; Monidipa Dasgupta; Meera Agar; Jose L Pereira; David C Currow; Shirley H Bush
Journal:  BMC Palliat Care       Date:  2020-10-21       Impact factor: 3.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.